Pancreatic Cancer
One of the deadliest major cancers, often diagnosed late; most cases are driven by KRAS mutations.
If Pancreatic Cancer is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- The Long, Remarkable History of KRAS and Pancreatic Cancer: From Gene Discovery to Successful Therapeutic Targeting. · Mod Pathol · 2026-08-05
- FDA grants breakthrough status to Lilly’s KRAS G12C inhibitor for pancreatic cancer - gxpnews.net · KRAS Mutation Research (Google News) · 2026-08-05
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - PR Newswire · KRAS Mutation Research (Google News) · 2026-08-03
- Lilly's olomorasib earns FDA Breakthrough Therapy designation for KRAS G12C pancreatic cancer - AllSci · KRAS Mutation Research (Google News) · 2026-08-03
- Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN) - TipRanks · KRAS Mutation Research (Google News) · 2026-07-29
- KRAS inhibitors MRTX1133 or daraxonrasib synergize with anti-CTLA4 in pancreatic cancer - Bioengineer.org · KRAS Mutation Research (Google News) · 2026-07-27
What the reporting says
It shows up alongside KRAS (56), FDA (16).
Two steps out: Colorectal Cancer (through KRAS, 56 shared stories on the weaker link); Immunotherapy (through KRAS, 18 shared stories on the weaker link); Egfr (through KRAS, 17 shared stories on the weaker link); AI (through FDA, 16 shared stories on the weaker link).
Tracked since Mar 12, with coverage on 47 separate days — concentrated in Oncology and Pubmed Targeted.